Five Prime Therapeutics Gross Profit

Five Prime Therapeutics posts a gross profit of $13M as of December 2020. That compares with $15M in the prior-year period — down 11.4% year over year. That is below the Healthcare sector average of $67B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Five Prime Therapeutics's gross profit was $15M. The latest reading is $13M — a 11.4% year-over-year decrease (period ending December 2020). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $67B is typical. Five Prime Therapeutics's $13M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Five Prime Therapeutics's financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for FPRX's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $67B), and (3) consistency with growth and profitability. This page covers the first two; Five Prime Therapeutics's other metric pages and overview cover the third.